Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cefoxitin in ESBL-producing E. coli Acute Pyelonephritis
NCT01820793Phase 2Terminated
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2013
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cefoxitin in acute pyelonephritis, sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Clinical and microbiological response at 10 days. Started May 2013; status: terminated.
02
Drugs
cefoxitin
03
Conditions
acute pyelonephritis
Beyond the preview
Go deeper on NCT01820793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01820793.